CAR-T Pipeline Insight | Key Companies – Pepromene bio, Oxford Biomedica, Orgenesis, Oncternal Therapeutics, Novartis Pharma, Noile-Immune Biotech, Nanjing KAEDI Biotech, Mustang Bio and Others

CAR-T Pipeline Insight | Key Companies – Pepromene bio, Oxford Biomedica, Orgenesis, Oncternal Therapeutics, Novartis Pharma, Noile-Immune Biotech, Nanjing KAEDI Biotech, Mustang Bio and Others

May 24
15:20 2023
CAR-T Pipeline Insight | Key Companies - Pepromene bio, Oxford Biomedica, Orgenesis, Oncternal Therapeutics, Novartis Pharma, Noile-Immune Biotech, Nanjing KAEDI Biotech, Mustang Bio and Others

DelveInsight’s, “CAR-T Pipeline Insights 2023” report provides comprehensive insights about 120+ companies and 460+ pipeline drugs in the CAR-T pipeline landscape. It covers the CAR-T pipeline drug profiles, including CAR-T clinical trials and nonclinical stage products. It also covers the CAR-T therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the CAR-T Pipeline Report

 

  • Over 120+ CAR T companies are evaluating 460+ CAR T-cell therapies in various stages of development, and their anticipated acceptance in the CAR T-cell therapy market would significantly increase market revenue.

 

  • The CAR-T Pipeline Companies include Ziopharm Oncology Inc. and Intrexon, Yake Biotechnology, Xyphos Biosciences, Xi’An Yufan Biotechnology, Wuhan Sian Medical Technology, Wuhan Bio-Raid Biotechnology, Wugen, WindMIL Therapeutics, Wellington Zhaotai Therapies, VorBio, VCANBIO Cell & Gene Engineering Corporation Ltd, UWELL Biopharma, Transgene, TrakCel, ToolGen, Tmunity Therapeutics, Timmune Biotech, TILT Biotherapeutics, Tianjin Mycure Medical Technology, The Beijing Pregene Science and Technology Company, Tessa Therapeutics Ltd., TC BioPharm, Targazyme, Takeda / Noile-Immune Biotech, Synthekine, SymVivo, Sorrento Therapeutics, Sinobioway Cell Therapy Co., Ltd., Shenzhen BinDeBio, Shanghai Unicar-Therapy Bio-medicine Technology, Shanghai Longyao Biotechnology, Shanghai GeneChem Co., Ltd., Shanghai Biomed-union Biotechnology, Servier, Sensei Biotherapeutics, Senlang Bio, Sangamo, Sana Biotechnology, REGENERON, PTX Therapeutics, Protheragen, Pregene (ShenZhen) Biotechnology Company, Precision BioSciences, Precigen, Poseida Therapeutics, PersonGen BioTherapeutics (Suzhou) Co., Ltd., Pepromene bio, Oxford Biomedical, Orgenesis, Oncternal Therapeutics, Novartis Pharmaceuticals, Noile-Immune Biotech, Nanjing KAEDI Biotech, Mustang Bio, MolMed, Minerva Biotechnologies, Miltenyi Biotec, Medisix Therapeutics, Maxcyte, Luminary Therapeutics, Liminatus Pharma, Kuur Therapeutics, Kite Pharma, Kiromic BioPharma, Kecellitics Biotech Company Ltd, KAEDI, JW Therapeutics, Janssen Pharmaceuticals, Intellia Therapeutics, Innovent Biologics, Innovative Cellular Therapeutics, InnoBation, IN8Bio, Immunicum, Immuneel, Immune Therapeutics, iCell Gene Therapeutics, iCarTAB BioMed, Hunan Zhaotai Yongren Medical Innovation, Humorigin, HRAIN Biotechnology, Henan Hualong Biotechnology, Hemalogix, Helocyte, Helix BioPharma, Hebei Senlang Biotechnology Inc., Ltd., Guangzhou Bio-gene Technology, Guangdong Zhaotai InVivo Biomedicine Co. Ltd., Grand Vista Biotechnology, Gracell Biotechnology, Glycotype, GlaxoSmithKline, Gilead Sciences, Genus oncology, GC Cell, Fundamenta Therapeutics, Fujifilm Holdings Corporation, Formula Pharmaceuticals, Fate Therapeutics, FastBack Bio, Exuma, Eutilex/Utilities, Eureka Therapeutics, Enlivex Therapeutics Ltd, Endocyte, Elpis Biopharmaceuticals, Curocell, CRISPR Therapeutics, Creative Biolabs, Cogent Biosciences, Chongqing Precision Biotechnology Co., Ltd., Chimeric Therapeutics, Celyad Oncology SA, Cellular Biomedicine Group, Cellectis, Celgene, CASI Pharmaceuticals/Juventas Cell Therapy, Cartherics, Cartesian Therapeutics, Carsgen Therapeutics, CARsgen, Carina Biotech, Caribou Biosciences, Bristol-Myers Squibb, BrightPath Therapeutics, Bluebird Bio, Biosceptre, BioNTech, Bioceltech Therapeutics, Bioatla, Benitec Biopharma Limited, Bellicum Pharmaceuticals, Beijing Mario Biotech, Beam Therapeutics, Autolus Limited, Aurora Biopharma, Atreca/Xenor, Atossa Therapeutics, Atara Biotherapeutics, Arcellx Inc, Arbele Limited, Apceth Biopharma, Anti-CD19 chimeric antigen receptor T cell therapy – Avalon GloboCare; AVA-001 – Avalon GloboCare, Anixa Biosciences, Amgen/Kite Pharma, Allogene Therapeutics, Allife Medical Science and Technology, AgenTus Therapeutics, AffyImmune Therapeutics, Adicet Bio, Adagene, Actinium Pharmaceuticals, AbCLon, AbbVie, Obsidian Therapeutics, Beijing Biohealthcare Biotechnology, and others

 

  • Promising CAR-T Pipeline Therapies include Kymriah, CT103A, CEA CAR-T, Descartes-11, CNCT19, CTL119, P-BCMA-101, CD19/CD20/CD22/CD30 CAR T-cell therapy, CD19-targeted CAR T-cells, EPCAM-targeted CAR-T cells, TT11, CD19+CD22 CAR-T cell sequential therapy, CART-19/22, MB-CART2019.1, JCAR017, AUTO4, AUTO3, IM19 CAR-T, CSG-CD19, CT053, Descartes-08, Orvacabtagene autoleucel, CAR-T CD30, PCAR-19B, BCMA CAR-T cells, CD123 CAR-T cells, CD19 CAR-T cells, ET140202, CIK-CAR.CD19, BG-T19, Autologous CD19-targeting CAR T cells (Senl-001), MB-102, Autologous CAR-T CD44v6 cell therapy, AU101, ATA2271, AU105, AUTO1, BPX-601, Anti-CD22 CAR, CAR-T cells targeting CD19 and CD22, huMNC2-CAR44 CAR T-cells, CD19-CART, ALLO-501A, AUTO1/22, ET 1402L1-CART, BPX-603, CAR-CD44v6, MB-106 (CD20 CAR), Anti-MUC1 CAR-T cells, PCAR-019, PBCAR0191, PBCAR20A, PBCAR269A, BCMA CAR T-cells, CAR19 CAR T cells, MG7-CART Cells, GPC3 – CART Cells, Anti-CD19 and Anti-CD20 CAR-T Cells, Humanized CD19 CAR-T cells, Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy, Mesothelin CAR-T cell therapy, and others

 

  • The CAR-T Companies and academics are working to assess challenges and seek opportunities that could influence CAR-T R&D. The CAR-T pipeline therapies under development are focused on novel approaches to treat/improve CAR-T.

 

Request a sample and discover the recent breakthroughs happening in the CAR-T Pipeline landscape @ CAR-T Pipeline Outlook Report

 

CAR-T Overview

CAR-T is a type of treatment in which a patient’s T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called chimeric antigen receptor T-cell therapy.

 

CAR-T Emerging Drugs

 

JWCAR029: JW Therapeutics

JWCAR029 is a CAR-T cell product targeting CD19, which is intended to treat late-stage lymphoma and leukemia (Second-line therapy or greater). The molecule is in phase-II stage of development. Initially, JWCAR029 is being studied for the treatment of B-cell malignancies focusing on relapsed and refractory DCBCL. In June 2020, the National Medical Products Administration (“NMPA”) accepted for review its NDA relating to relma-cel as a third-line treatment for DLBCL.

 

CT 103A: Innovent Biologics

CT103A is an innovative therapy co-developed by IASO BIO and Innovent. Previous studies indicate patients with relapsed/refractory multiple myeloma (RRMM) who received high-dose BCMA-targeting CAR-T cells may achieve better remission but have worse adverse events. Moreover, once the disease progresses again, the re-infusion of CAR-T cells is not effective. To solve this dilemma, CT103A has been developed, a lentiviral vector containing a CAR structure with a fully human scFv, CD8a hinger and transmembrane, 4-1BB co-stimulatory and CD3z activation domains. Based on strict selection and screening, utilizing a proprietary in-house optimization platform, the construct of the CT103A CAR-T is potent and persistent. According to the company’s pipeline, the drug is currently in Phase III stage of clinical trial evaluation to treat multiple myeloma.

 

CEA CAR T: Sorrento Therapeutics

Sorrento Therapeutics through its wholly-owned subsidiary TNK Therapeutics is developing CEA CAR T. It is a CAR T-cells targeting carcinoembryonic antigen (CEA). The drug is in phase II/III stage of development.

 

Descartes-11: Cartesian Therapeutics

Descartes-011 are autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor. Descartes-11 is currently in phase II clinical trials to treat patients with multiple myeloma in an outpatient setting.

 

CTL119: Novartis

CTL119 (CD19 CAR) is a humanized CD19 CAR under development by Novartis in collaboration with the University of Pennsylvania and currently is in Phase II stage for the treatment of Acute Lymphoid Leukemia. CTL119 is produced with a patient’s T-cells, some of which are removed and then reprogrammed in Penn’s Clinical Cell and Vaccine Production Facility with a gene transfer technique designed to demonstrate the T cells to target and kill tumor cells. The engineered cells contain an antibody-like protein known as a CAR, which is designed to bind to CD19 protein on the surface of cancerous B cells. The modified “hunter” cells are then infused back into the patient’s body, where they multiply and are believed to attack the cancer cells.

 

TT11: Tessa Therapeutics

Tessa Therapeutics is developing TT11 (CD30-CAR-Tcells) in phase II stage of clinical development for the treatment of Relapsed/Refractory Hodgkin Lymphoma. The immunotherapy is CD30 targeted CAR-T cell therapy.

 

CD19-targeted CAR-T cells: Sinobioway Cell Therapy

CD19-targeted CAR T-cells is under development by Sinobioway Cell Therapy Co., Ltd. The therapeutic candidate is in Phase II stage of development for the treatment of Recurrent or Refractory Diffuse Large B-cell Lymphoma and Recurrent or Refractory Acute Non-T Lymphocyte Leukemia. The therapeutic candidate targets CD-19.

 

MB-CART2019.1: Miltenyi Biomedicine

MB-CART2019.1 is an autologous pLTG1497-transduced CAR T-cells. Miltenyi Biomedicine is developing MB-CART2019.1 for the treatment of Diffuse Large B Cell Lymphoma and B-cell Non Hodgkin Lymphoma. Zamtocabtagene autoleucel is a proposed International Nonproprietary Name of MB-CART2019.1.

 

EPCAM-targeted CAR T-cells: Sinobioway Cell Therapy

EPCAM-targeted CAR T-cells is under development by Sinobioway Cell Therapy Co., Ltd. The therapeutic candidate is in Phase II stage of development for the treatment of Liver Cancer and Stomach Cancer. The therapeutic candidate targets Epithelial Cell Adhesion Molecule (EPCAM). It acts by inducing lysis of tumor cells expressing Epithelial Cell Adhesion Molecule (EPCAM).

 

For further information, refer to the detailed CAR-T Drugs Launch, CAR-T Developmental Activities, and CAR-T News, click here for CAR-T Ongoing Clinical Trial Analysis

 

CAR-T Pipeline Therapeutics Assessment

There are approx. 120+ key companies which are developing the therapies for CAR-T. The companies which have their CAR-T drug candidates in the most advanced stage, i.e. Preregistration include, JW Therapeutics.

 

CAR-T Pipeline Segmentation

 

 

Phases

DelveInsight’s report covers around 460+ products under different phases of clinical development like

  • Late-stage products (Phase II and Phase II/III)
  • Mid-stage products (Phase II and Phase II/III)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

CAR-T pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Intratumoral
  • Mechanism of Action

 

Products have been categorized under various Mechanisms of Action such as

  • Lymphocyte replacements
  • Immunologic cytotoxicity
  • Product Type

 

Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.

 

Find out more about the CAR-T Pipeline Segmentation, Therapeutics Assessment, and CAR-T Emerging Drugs @ CAR-T Treatment Landscape

 

Scope of the CAR-T Pipeline Report

 

  • Coverage- Global

 

  • Companies- Ziopharm Oncology Inc. and Intrexon, Yake Biotechnology, Xyphos Biosciences, Xi’An Yufan Biotechnology, Wuhan Sian Medical Technology, Wuhan Bio-Raid Biotechnology, Wugen, WindMIL Therapeutics, Wellington Zhaotai Therapies, VorBio, VCANBIO Cell & Gene Engineering Corporation Ltd, UWELL Biopharma, Transgene, TrakCel, ToolGen, Tmunity Therapeutics, Timmune Biotech, TILT Biotherapeutics, Tianjin Mycure Medical Technology, The Beijing Pregene Science and Technology Company, Tessa Therapeutics Ltd., TC BioPharm, Targazyme, Takeda / Noile-Immune Biotech, Synthekine, SymVivo, Sorrento Therapeutics, Sinobioway Cell Therapy Co., Ltd., Shenzhen BinDeBio, Shanghai Unicar-Therapy Bio-medicine Technology, Shanghai Longyao Biotechnology, Shanghai GeneChem Co., Ltd., Shanghai Biomed-union Biotechnology, Servier, Sensei Biotherapeutics, Senlang Bio, Sangamo, Sana Biotechnology, REGENERON, PTX Therapeutics, Protheragen, Pregene (ShenZhen) Biotechnology Company, Precision BioSciences, Precigen, Poseida Therapeutics, PersonGen BioTherapeutics (Suzhou) Co., Ltd., Pepromene bio, Oxford Biomedical, Orgenesis, Oncternal Therapeutics, Novartis Pharmaceuticals, Noile-Immune Biotech, Nanjing KAEDI Biotech, Mustang Bio, MolMed, Minerva Biotechnologies, Miltenyi Biotec, Medisix Therapeutics, Maxcyte, Luminary Therapeutics, Liminatus Pharma, Kuur Therapeutics, Kite Pharma, Kiromic BioPharma, Kecellitics Biotech Company Ltd, KAEDI, JW Therapeutics, Janssen Pharmaceuticals, Intellia Therapeutics, Innovent Biologics, Innovative Cellular Therapeutics, InnoBation, IN8Bio, Immunicum, Immuneel, Immune Therapeutics, iCell Gene Therapeutics, iCarTAB BioMed, Hunan Zhaotai Yongren Medical Innovation, Humorigin, HRAIN Biotechnology, Henan Hualong Biotechnology, Hemalogix, Helocyte, Helix BioPharma, Hebei Senlang Biotechnology Inc., Ltd., Guangzhou Bio-gene Technology, Guangdong Zhaotai InVivo Biomedicine Co. Ltd., Grand Vista Biotechnology, Gracell Biotechnology, Glycotype, GlaxoSmithKline, Gilead Sciences, Genus oncology, GC Cell, Fundamenta Therapeutics, Fujifilm Holdings Corporation, Formula Pharmaceuticals, Fate Therapeutics, FastBack Bio, Exuma, Eutilex/Utilities, Eureka Therapeutics, Enlivex Therapeutics Ltd, Endocyte, Elpis Biopharmaceuticals, Curocell, CRISPR Therapeutics, Creative Biolabs, Cogent Biosciences, Chongqing Precision Biotechnology Co., Ltd., Chimeric Therapeutics, Celyad Oncology SA, Cellular Biomedicine Group, Cellectis, Celgene, CASI Pharmaceuticals/Juventas Cell Therapy, Cartherics, Cartesian Therapeutics, Carsgen Therapeutics, CARsgen, Carina Biotech, Caribou Biosciences, Bristol-Myers Squibb, BrightPath Therapeutics, Bluebird Bio, Biosceptre, BioNTech, Bioceltech Therapeutics, Bioatla, Benitec Biopharma Limited, Bellicum Pharmaceuticals, Beijing Mario Biotech, Beam Therapeutics, Autolus Limited, Aurora Biopharma, Atreca/Xenor, Atossa Therapeutics, Atara Biotherapeutics, Arcellx Inc, Arbele Limited, Apceth Biopharma, Anti-CD19 chimeric antigen receptor T cell therapy – Avalon GloboCare; AVA-001 – Avalon GloboCare, Anixa Biosciences, Amgen/Kite Pharma, Allogene Therapeutics, Allife Medical Science and Technology, AgenTus Therapeutics, AffyImmune Therapeutics, Adicet Bio, Adagene, Actinium Pharmaceuticals, AbCLon, AbbVie, Obsidian Therapeutics, Beijing Biohealthcare Biotechnology, and others

 

  • Pipeline Therapies- Kymriah, CT103A, CEA CAR-T, Descartes-11, CNCT19, CTL119, P-BCMA-101, CD19/CD20/CD22/CD30 CAR T-cell therapy, CD19-targeted CAR T-cells, EPCAM-targeted CAR-T cells, TT11, CD19+CD22 CAR-T cell sequential therapy, CART-19/22, MB-CART2019.1, JCAR017, AUTO4, AUTO3, IM19 CAR-T, CSG-CD19, CT053, Descartes-08, Orvacabtagene autoleucel, CAR-T CD30, PCAR-19B, BCMA CAR-T cells, CD123 CAR-T cells, CD19 CAR-T cells, ET140202, CIK-CAR.CD19, BG-T19, Autologous CD19-targeting CAR T cells (Senl-001), MB-102, Autologous CAR-T CD44v6 cell therapy, AU101, ATA2271, AU105, AUTO1, BPX-601, Anti-CD22 CAR, CAR-T cells targeting CD19 and CD22, huMNC2-CAR44 CAR T-cells, CD19-CART, ALLO-501A, AUTO1/22, ET 1402L1-CART, BPX-603, CAR-CD44v6, MB-106 (CD20 CAR), Anti-MUC1 CAR-T cells, PCAR-019, PBCAR0191, PBCAR20A, PBCAR269A, BCMA CAR T-cells, CAR19 CAR T cells, MG7-CART Cells, GPC3 – CART Cells, Anti-CD19 and Anti-CD20 CAR-T Cells, Humanized CD19 CAR-T cells, Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy, Mesothelin CAR-T cell therapy, and others

 

  • CAR-T Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for CAR-T Pipeline Companies and Therapies, click here @ CAR-T Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. CAR-T: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Preregistration)
  7. JWCAR029: JW therapeutics
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. Descartes-11: Cartesian Therapeutics
  11. Drug profiles in the detailed report…..
  12. Early stage products (Phase I/II)
  13. CSG-CD19: Carsgen therapeutics
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. CAR-T Key Companies
  17. CAR-T Key Products
  18. CAR-T- Unmet Needs
  19. CAR-T- Market Drivers and Barriers
  20. CAR-T- Future Perspectives and Conclusion
  21. CAR-T Analyst Views
  22. CAR-T Key Companies
  23. Appendix

 

Got Queries? Find out the related information on CAR-T Mergers and acquisitions, CAR-T Licensing Activities @ CAR-T Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Categories